Orange Book product · Generic (ANDA)
CEFDINIR
CEFDINIR
At a glance
Dec 14, 2007
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 14, 2007
18 yr 9 mo ago
Today
Pharmaceutical detail
Active ingredient
CEFDINIR
Strength
250MG/5ML
Dosage form
FOR SUSPENSION
Route
ORAL
TE code
AB
Application
ANDA 065473
Product number
002
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
Yes
Active-ingredient family
View full familyGeneric (ANDA) of CEFDINIR
- 1997OMNICEFBrand (NDA)
NDA 050739 · ABBVIE
- 1997OMNICEFBrand (NDA)
NDA 050749 · ABBVIE
- 2021CEFDINIRGeneric (ANDA)
ANDA 210220 · ALKEM LABS LTD
- 2021CEFDINIRGeneric (ANDA)
ANDA 210534 · ALKEM LABS LTD
- 2008CEFDINIRGeneric (ANDA)
ANDA 065434 · AUROBINDO PHARMA
- 2007CEFDINIRGeneric (ANDA)
ANDA 065418 · ANDA REPOSITORY
- 2007CEFDINIRGeneric (ANDA)
ANDA 065429 · ANDA REPOSITORY
- 2007CEFDINIRGeneric (ANDA)
ANDA 065368 · TEVA PHARMS
- 2007CEFDINIRGeneric (ANDA)
ANDA 065332 · TEVA PHARMS
- 2007CEFDINIRGeneric (ANDA)
ANDA 065330 · CHARTWELL RX
- 2007CEFDINIRGeneric (ANDA)
ANDA 065337 · CHARTWELL RX
- 2006CEFDINIRGeneric (ANDA)
ANDA 065259 · LUPIN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
